Boogaerts 2003.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 259, multiple myeloma, Non‐Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin disease, ovarian, bone, gastrointestinal, respiratory, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = 150 IU/kg sc TIW hb‐target = 12‐14 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: QoL; secondary: direct and indirect costs
Notes	study number = 36158
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization